Pruritus (PDQ®): Supportive care - Health Professional Information [NCI] - Get More Information From NCI
CALL 1-800-4-CANCER For more information,U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your ...
Essiac/Flor Essence (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - To Learn More About CAM
NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE (NCCAM) The National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) facilitates research and evaluation of complementary and alternative practices,and provides information about a variety of approaches to health professionals and the public. NCCAM Clearinghouse Post Office Box 7923 ...
Lymphedema (PDQ®): Supportive care - Patient Information [NCI] - nci_ncicdr0000062799-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Lymphedema
Laryngeal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Laryngeal Cancer
The staging system for laryngeal cancer is clinical and based on the best possible estimate of the extent of disease before treatment. The assessment of the primary tumor is based on inspection and palpation when possible and by both indirect mirror examination and direct endoscopy when necessary. The tumor must be confirmed histologically,and any other pathological data obtained on biopsy may ...
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Changes to This Summary (01 / 04 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Cancer Genetics Overview (PDQ®): Genetics - Health Professional Information [NCI] - Methods of Genetic Analysis and Gene Discovery
Linkage AnalysesThe recognition that cancer clusters within families has led many investigators to collect data on multiple-case families with the goal of localizing cancer susceptibility genes through linkage studies.Linkage studies are typically performed on high-risk kindreds, in whom multiple cases of a particular disease have occurred, in an effort to identify disease susceptibility genes. Linkage analysis statistically compares the genotypes between affected and unaffected individuals and looks for evidence that known genetic markers are inherited along with the disease trait. If such evidence is found (linkage), it provides statistical data that the chromosomal region near the marker also harbors a disease susceptibility gene. Once a genomic region of interest has been identified through linkage analysis, additional studies are required to prove that there truly is a susceptibility gene at that position. Linkage analysis is affected by the following:Family size and
Cancer Genetics Risk Assessment and Counseling (PDQ®): Genetics - Health Professional Information [NCI] - The Option of Genetic Testing
Factors to Take into Consideration in Offering Testing Indications for testing Experts recommend offering genetic testing when a risk assessment suggests the presence of an inherited cancer syndrome for which specific genes have been identified. The American Society of Clinical Oncology (ASCO) Policy Statement on Genetic Testing for Cancer Susceptibility proposes that genetic testing be offered ...
Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Treatment of extensive regional disease has thus far not had well-documented success by either radiation or systemic chemotherapy. Patients with extensive regional disease should be considered for clinical trials.
Levels of Evidence for Cancer Screening and Prevention Studies (PDQ®): Screening - Health Professional Information [NCI] - Introduction
The Levels of Evidence for the Screening and Prevention statements are being revised. This document is a work in progress. To date,these Levels of Evidence have been applied to the following Screening and Prevention statements: Screening for Bladder and Other Urothelial Cancers; Screening for Cervical Cancer; Screening for Esophageal Cancer; Screening for Gastric Cancer; Screening for Lung ...
Rectal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage 0 Rectal Cancer
Stage 0 rectal cancer is the most superficial of all rectal lesions and is limited to the mucosa without invasion of the lamina propria. Because of its superficial nature, surgical and other procedures may be limited. Standard treatment options:Local excision or simple polypectomy.Full-thickness rectal resection by the transanal or transcoccygeal route for large lesions not amenable to local excision.Endocavitary radiation therapy.[2,3,4]Local radiation therapy.Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage 0 rectal cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.General information about clinical trials is also available from the NCI Web site.References: Bailey HR, Huval WV, Max E, et al.: Local excision of carcinoma of the rectum for cure. Surgery 111 (5): 555-61, 1992. Kodner IJ, Gilley MT, Shemesh EI, et al.: Radiation